MMED earnings analysis
What we found in MMED's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q text does not include the financial statements or MD&A needed to assess quarterly revenue, margins, EPS, segment trends, balance-sheet changes, or cash flow. The principal quantified exposure disclosed is foreign currency: approximately $499 million of forward-contract notional as of July 31, 2026, with an estimated $50 million fair-value sensitivity to a uniform 10% currency move. Management reported effective disclosure controls and no material changes to the company’s 2026 Form 10-K risk factors.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Currency exposure partially hedged
- The company had approximately $499 million of outstanding foreign-currency forward contracts as of July 31, 2026, providing economic hedging for certain currency exposures.
- Disclosure controls remained effective
- Management reported that its disclosure controls were effective as of the end of the period, and stated that there had been no changes during the quarter that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
- Hedge offsets underlying FX exposure
- The filing states that a uniform 10% move in the U.S. dollar would change the fair value of the outstanding currency contracts by approximately $50 million, with gains and losses generally offset by the underlying exposures.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material foreign-exchange exposure
- The company remains exposed to foreign-exchange movements affecting earnings, cash flows, assets, and liabilities. The $499 million notional hedge portfolio would experience an estimated $50 million fair-value change under a uniform 10% currency move, before considering offsets from the underlying exposures.
- No new risk-factor disclosures
- The filing states that there were no material changes to the risk factors presented in the 2026 Form 10-K; therefore, the report does not identify a newly added or escalated risk factor versus the prior annual filing.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the extracted 10-Q text; prior outlook information appeared in the 8-K and earnings materials.
The filing reads about the same as the one before it.
What came before.
- 10-K · June 29, 2026
- MiniMed Group, Inc. (MMED) reported strong revenue growth of 14% YoY, reaching $3.1 billion. Although operating losses persist, improvements in gross profit margins were observed, primarily driven by increased sales of…
- 10-Q · April 17, 2026
- MiniMed Group reported quarter revenue growth to $790.0M (up $103.0M or ~15% y/y) but posted a $111.0M net loss for the quarter, driven by a $118.0M contract termination/asset write‑off charge and elevated restructuring…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MMED makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever